TBPH
Theravance Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · KY
$17.02
−0.12%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$17.03
From 52W high−17.94%
Volume651835.00
Market cap$883.66M
P/E (TTM)16.0x
P/S (TTM)8.5x
Div yield—
Key dataSep 18, 2026
Open
$17.03
From 52W high
−17.94%
Volume
651835.00
Market cap
$883.66M
ValuationView details →
P/E (Fwd)
5.9x
EV/EBITDA
7.8x
P/E (TTM)
16.0x
RSI (14)
54.2
MomentumView details →
1D Return
−0.12%
YTD Return
−8.98%
SummaryUpdated Jun 1, 2026
Theravance Biopharma, Inc. (NASDAQ:TBPH) is a biopharmaceutical company founded in 2013 and incorporated in the Cayman Islands with operations based in George Town. The company emerged as a spinoff focused on developing and commercializing respiratory medicines and other therapeutic treatments. Theravance operates primarily in the United States, Europe, and Asia, with a concentrated focus on respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), and rare neurological conditions. The company has transitioned from a broad research-focused organization to a more streamlined entity concentrating on its core commercial asset and late-stage pipeline candidates.
Similar companies
Latest newsMore news →
Theravance Biopharma is facing several lawsuits seeking to block its acquisition by Zymeworks.10d agoEmpowered Funds LLC acquired a new position in Theravance Biopharma, Inc., purchasing 55,463 shares valued at approximately $900,000, representing 0.11% ownership.33d agoHalper Sadeh LLC announced an investigation into Theravance Biopharma's pending acquisition by Zymeworks Inc. to determine whether shareholders are receiving a fair price and whether the board complied with securities laws and fiduciary duties.36d ago